Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment-Reference-Cited by-同舟云学术

Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment

Published:2022-06-05 Issue:4 Volume:40 Page:734-742
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Sartor Chiara¹^ORCID,Arpinati Mario²,Chirumbolo Gabriella¹,Dozza Luca¹,Cristiano Gianluca¹^ORCID,Nanni Jacopo¹,Marconi Giovanni¹³^ORCID,Robustelli Valentina¹,Vigliotta Ilaria²^ORCID,Parisi Sarah²,Terragna Carolina²,Testoni Nicoletta¹²,Paolini Stefania²,Martinelli Giovanni³,Curti Antonio²,Cavo Michele¹²,Papayannidis Cristina²^ORCID

Affiliation:

1. Dipartimento di Medicina Specialistica Istituto di Ematologia "Seràgnoli" Diagnostica e Sperimentale Università degli Studi di Bologna Bologna Italy

2. IRCCS Azienda Ospedaliero‐Universitaria di Bologna Istituto di Ematologia “Seràgnoli” Bologna Italy

3. Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS Meldola Italy

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.3029

Reference33 articles.

1. Acute lymphoblastic leukemia: a comprehensive review and 2017 update

2. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia

3. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group

4. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

5. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions;Cancer;2024-08-02

2. Immune therapies of B-cell acute lymphoblastic leukaemia in children and adults;Critical Reviews in Oncology/Hematology;2024-04

3. Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations;Frontiers in Immunology;2023-08-03

4. Switching from salvage chemotherapy to immunotherapy in adult B-cell acute lymphoblastic leukemia;Blood Reviews;2023-05